Literature DB >> 10728701

BRCA1 and BRCA2 have a limited role in familial prostate cancer.

C S Sinclair1, R Berry, D Schaid, S N Thibodeau, F J Couch.   

Abstract

Epidemiological studies have suggested that the breast cancer susceptibility genes, BRCA1 and BRCA2, may be involved in the development of prostate cancer. Several studies have screened prostate cancer populations for the presence of BRCA1 and BRCA2 mutations, with few mutations identified. In this study, 22 high-risk prostate cancer families (at least three cases of prostate cancer) were screened by conformation-sensitive gel electrophoresis (CSGE) for mutations in BRCA1 and BRCA2. To maximize the chance of finding mutations in these two genes, families were also selected for the presence of at least two cases of breast and/or ovarian cancer. We identified one previously reported BRCA2 missense mutation and two previously unreported BRCA2 intron polymorphisms. No BRCA1 or BRCA2 truncating mutations were detected. Thus, BRCA1 and BRCA2 appear to have a limited role in familial prostate cancer, and families with both prostate and breast cancer may result from mutations in other predisposition genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728701

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer.

Authors:  Marc Tischkowitz; Nelly Sabbaghian; Anna M Ray; Ethan M Lange; William D Foulkes; Kathleen A Cooney
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

2.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Authors:  Rong Na; S Lilly Zheng; Misop Han; Hongjie Yu; Deke Jiang; Sameep Shah; Charles M Ewing; Liti Zhang; Kristian Novakovic; Jacqueline Petkewicz; Kamalakar Gulukota; Donald L Helseth; Margo Quinn; Elizabeth Humphries; Kathleen E Wiley; Sarah D Isaacs; Yishuo Wu; Xu Liu; Ning Zhang; Chi-Hsiung Wang; Janardan Khandekar; Peter J Hulick; Daniel H Shevrin; Kathleen A Cooney; Zhoujun Shen; Alan W Partin; H Ballentine Carter; Michael A Carducci; Mario A Eisenberger; Sam R Denmeade; Michael McGuire; Patrick C Walsh; Brian T Helfand; Charles B Brendler; Qiang Ding; Jianfeng Xu; William B Isaacs
Journal:  Eur Urol       Date:  2016-12-15       Impact factor: 20.096

3.  Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.

Authors:  Brennan Decker; Danielle M Karyadi; Brian W Davis; Eric Karlins; Lori S Tillmans; Janet L Stanford; Stephen N Thibodeau; Elaine A Ostrander
Journal:  Am J Hum Genet       Date:  2016-04-14       Impact factor: 11.025

4.  Germline mutations in HOXB13 and prostate-cancer risk.

Authors:  Charles M Ewing; Anna M Ray; Ethan M Lange; Kimberly A Zuhlke; Christiane M Robbins; Waibhav D Tembe; Kathleen E Wiley; Sarah D Isaacs; Dorhyun Johng; Yunfei Wang; Chris Bizon; Guifang Yan; Marta Gielzak; Alan W Partin; Vijayalakshmi Shanmugam; Tyler Izatt; Shripad Sinari; David W Craig; S Lilly Zheng; Patrick C Walsh; James E Montie; Jianfeng Xu; John D Carpten; William B Isaacs; Kathleen A Cooney
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

5.  The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Authors:  Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

6.  Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.

Authors:  Ilir Agalliu; Robert Gern; Suzanne Leanza; Robert D Burk
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 7.  The role of the BRCA2 gene in susceptibility to prostate cancer revisited.

Authors:  Elaine A Ostrander; Miriam S Udler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

8.  Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.

Authors:  Hagit Schayek; Kathy Haugk; Shihua Sun; Lawrence D True; Stephen R Plymate; Haim Werner
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

9.  Common variation in the BRCA1 gene and prostate cancer risk.

Authors:  Julie A Douglas; Albert M Levin; Kimberly A Zuhlke; Anna M Ray; Gregory R Johnson; Ethan M Lange; David P Wood; Kathleen A Cooney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06-21       Impact factor: 4.254

10.  Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin.

Authors:  Cezary Cybulski
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.